| Primary |
| Hiv Infection |
83.0% |
| Product Used For Unknown Indication |
2.4% |
| Acquired Immunodeficiency Syndrome |
1.9% |
| Hypertension |
1.9% |
| Prophylaxis |
1.6% |
| Antiretroviral Therapy |
1.4% |
| Depression |
1.3% |
| Pneumocystis Jiroveci Pneumonia |
1.0% |
| Tuberculosis |
0.9% |
| Diabetes Mellitus |
0.6% |
| Hepatitis C |
0.6% |
| Hiv Test Positive |
0.5% |
| Type 2 Diabetes Mellitus |
0.5% |
| Dyslipidaemia |
0.4% |
| Prophylaxis Against Hiv Infection |
0.4% |
| Pulmonary Tuberculosis |
0.4% |
| Insomnia |
0.4% |
| Pain |
0.3% |
| Hypercholesterolaemia |
0.3% |
| Pyrexia |
0.3% |
|
| Drug Exposure During Pregnancy |
10.5% |
| Thrombocytopenia |
9.4% |
| Death |
9.2% |
| Rash |
9.0% |
| Vomiting |
7.2% |
| Exposure During Pregnancy |
4.8% |
| Cytolytic Hepatitis |
4.5% |
| Myalgia |
3.8% |
| Weight Decreased |
3.8% |
| Weight Increased |
3.8% |
| Renal Failure Acute |
3.7% |
| Rhabdomyolysis |
3.7% |
| Stevens-johnson Syndrome |
3.7% |
| Maternal Exposure During Pregnancy |
3.5% |
| Pyrexia |
3.4% |
| Virologic Failure |
3.4% |
| Blood Creatine Phosphokinase Increased |
3.3% |
| Headache |
3.3% |
| Depression |
3.1% |
| Rash Generalised |
3.1% |
|
| Secondary |
| Hiv Infection |
59.3% |
| Product Used For Unknown Indication |
12.3% |
| Antiretroviral Therapy |
5.1% |
| Maternal Exposure Timing Unspecified |
3.1% |
| Antiviral Treatment |
3.1% |
| Acquired Immunodeficiency Syndrome |
2.8% |
| Drug Exposure During Pregnancy |
2.1% |
| Hypertension |
2.1% |
| Drug Use For Unknown Indication |
1.9% |
| Prophylaxis |
1.2% |
| Depression |
1.0% |
| Diabetes Mellitus |
1.0% |
| Hepatitis C |
0.8% |
| Tuberculosis |
0.8% |
| Factor Viii Deficiency |
0.7% |
| Foetal Exposure During Pregnancy |
0.7% |
| Insomnia |
0.6% |
| Hiv Test Positive |
0.6% |
| Chronic Obstructive Pulmonary Disease |
0.5% |
| Anaemia |
0.5% |
|
| Drug Exposure During Pregnancy |
11.4% |
| Ventricular Hypertrophy |
10.5% |
| Foetal Exposure During Pregnancy |
6.9% |
| Renal Failure |
5.7% |
| Thrombocytopenia |
5.7% |
| Rash |
5.4% |
| Vomiting |
5.4% |
| Premature Baby |
5.1% |
| Rhabdomyolysis |
5.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.2% |
| Immune Reconstitution Syndrome |
4.2% |
| Umbilical Cord Abnormality |
3.9% |
| Cytolytic Hepatitis |
3.6% |
| Weight Decreased |
3.6% |
| Diabetes Mellitus |
3.3% |
| Neutropenia |
3.3% |
| Osteonecrosis |
3.3% |
| Sepsis |
3.3% |
| Weight Increased |
3.3% |
| Hyperlipidaemia |
3.0% |
|
| Concomitant |
| Hiv Infection |
53.2% |
| Product Used For Unknown Indication |
14.9% |
| Hepatitis C |
7.0% |
| Drug Use For Unknown Indication |
5.9% |
| Hiv Test Positive |
2.1% |
| Antiretroviral Therapy |
2.1% |
| Acquired Immunodeficiency Syndrome |
2.0% |
| Prophylaxis |
1.8% |
| Hypertension |
1.7% |
| Diabetes Mellitus |
1.4% |
| Drug Exposure During Pregnancy |
1.3% |
| Depression |
1.1% |
| Pain |
1.0% |
| Mycobacterium Avium Complex Infection |
0.8% |
| Chronic Hepatitis C |
0.7% |
| Factor Viii Deficiency |
0.6% |
| Insomnia |
0.6% |
| Kaposi's Sarcoma Aids Related |
0.6% |
| Antifungal Prophylaxis |
0.5% |
| Rash |
0.5% |
|
| Vomiting |
11.5% |
| Death |
6.7% |
| Myocardial Infarction |
6.7% |
| Anaemia |
5.9% |
| Rash |
5.9% |
| Weight Decreased |
5.9% |
| Pyrexia |
5.5% |
| Neuropathy Peripheral |
4.3% |
| Pancytopenia |
4.3% |
| Pneumonia |
4.3% |
| Thrombocytopenia |
4.3% |
| Off Label Use |
4.0% |
| Rash Maculo-papular |
4.0% |
| Renal Failure |
4.0% |
| Rhabdomyolysis |
4.0% |
| Uveitis |
4.0% |
| Weight Increased |
4.0% |
| Diarrhoea |
3.6% |
| Jaundice |
3.6% |
| Nausea |
3.6% |
|
| Interacting |
| Hiv Infection |
43.5% |
| Product Used For Unknown Indication |
32.9% |
| Antiretroviral Therapy |
3.5% |
| Hepatitis C |
3.5% |
| Antibiotic Therapy |
2.4% |
| Blood Cholesterol Increased |
2.4% |
| Ear Injury |
2.4% |
| Retroviral Infection |
2.4% |
| Gynaecomastia |
1.2% |
| Herpes Simplex |
1.2% |
| Hypercholesterolaemia |
1.2% |
| Hypertension |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
| Rectal Haemorrhage |
1.2% |
|
| Drug Interaction |
15.4% |
| Rhabdomyolysis |
15.4% |
| Adams-stokes Syndrome |
7.7% |
| Hepatotoxicity |
7.7% |
| Lactic Acidosis |
7.7% |
| Overdose |
7.7% |
| Red Blood Cell Count Abnormal |
7.7% |
| Tearfulness |
7.7% |
| Upper Extremity Mass |
7.7% |
| Weight Decreased |
7.7% |
| White Blood Cell Count Increased |
7.7% |
|
